-
Medical journals
- Career
Heart Failure
We recommend
Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
18. 4. 2024 Source: Heart FailureThe journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.
ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and…14. 3. 2024 Source: Heart Failure
Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in…4. 3. 2024 Source: Heart Failure
Articles on this topic
Webinar SGLT2i in ESC HF Guidelines vs. Real Practice
Dear Doctor, Boehringer Ingelheim, in collaboration with the 2nd Department of Internal…18. 11. 2021 Source: Heart Failure
Mechanisms of Cardioprotective Effects of SGLT2 Inhibitors
Inhibitors of sodium-glucose cotransporter 2 (SGLT2i, gliflozins) are a relatively new group…18. 11. 2021 Source: Heart Failure
Basic Cardiovascular Benefits of the Oral Antidiabetic Medication Empagliflozin
Type 2 diabetes mellitus is one of the main risk factors for cardiovascular (CV) diseases.…18. 11. 2021 Source: Heart Failure
Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the…27. 10. 2021 Source: Heart Failure
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has…20. 8. 2021 Source: Heart Failure
Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It…20. 8. 2021 Source: Heart Failure
LoginSubscribe
E-courses on this topic
Course detailAuthors: MUDr. Sylvie Štrégl Hrušková, prof. MUDr. Michal Vrablík, Ph.D., prof. MUDr. Vojtěch Melenovský, CSc., MUDr. Marie Lazárová
Conferences news
Go to records
Most read on this topic- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- Cardio-renal-metabolic syndrome in context
- The Latest Updates of ESC Recommendations for Heart Failure Treatment
- Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Journal on this topic
Related topicLogin#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career